| Aug 7, 2026Latest represented filing date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | Current covered snapshotCEO AND PRESIDENT · DirectorValuation observation Sep 25, 2026 | Common Stock: 65,292 sharesCurrent covered company value: $5.79M | Published current ownership snapshotForms represented: 4Owner filingsIssuer filings |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | AcquisitionSEC code MEffective Aug 7, 2026 · transaction dateReported units 40,000 shares · reported price 8.44 | Common StockReported position after transaction: 105,292 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | AcquisitionSEC code MEffective Aug 7, 2026 · transaction dateReported units 126,000 shares · reported price 8.44 | Common StockReported position after transaction: 231,292 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 10,384 shares · reported price 107.49 | Common StockReported position after transaction: 220,908 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 23,907 shares · reported price 108.05 | Common StockReported position after transaction: 197,001 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 2,373 shares · reported price 109.1 | Common StockReported position after transaction: 194,628 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 2,536 shares · reported price 110.02 | Common StockReported position after transaction: 192,092 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 800 shares · reported price 110.76 | Common StockReported position after transaction: 191,292 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 104,091 shares · reported price 107.96 | Common StockReported position after transaction: 87,102 shares | 4 filing0001669866-26-000010 |
| Aug 7, 2026Filed date | Dianthus Therapeutics, Inc. /DE/ (DNTH)Nasdaq | SaleSEC code SEffective Aug 7, 2026 · transaction dateReported units 21,909 shares · reported price 108.72 | Common StockReported position after transaction: 65,292 shares | 4 filing0001669866-26-000010 |